FDA approves revised dosage of HIV-combo drug
TITUSVILLE, N.J. — The Food and Drug Administration has approved a revised dosage for a drug combination, which includes a Johnson & Johnson drug, in HIV patients who have received treatment but whose virus has not become immune to the J&J drug.
Tibotec Therapeutics, a J&J subsidiary, announced the FDA’s approval in adults of a once-daily combination of its Prezista (darunavir) and Abbott’s Norvir (ritonavir), which combines 800 mg of Prezista with 100 mg of Norvir. The previously approved dosage was 600 mg of Prezista and 100 mg of Norvir taken twice per day.
“With this once-daily dosing recommendation, boosted Prezista is now a viable option for more treatment-experienced patients,” Tibotec president Glenn Mattes said. “This approval reflects Tibotec’s ongoing commitment to optimizing dosing strategies for HIV patients.”
Recreating islet cells can boost insulin production, study finds
NEW YORK — In patients with Type 1 diabetes, the islet cells of the pancreas are destroyed, thus eliminating the organ’s ability to produce insulin.
But researchers at Georgetown University have found a way to recreate them using cells from the testicles, according to published reports.
WebMD reported that the researchers took the testicular tissue, extracted the stem cells and used them to create new islet cells. Injecting them into the pancreases of mice with diabetes. The researchers found that the cells began to secrete insulin.
Data from the study were scheduled for presentation at the American Society of Cell Biology’s annual meeting in Philadelphia.
RediClinic’s operations to nearly double
HOUSTON — RediClinic has announced that it will open 20 new clinics inside H-E-B grocery stores across Texas, which will nearly double the number of RediClinics currently operating within H-E-B.
Eight clinics are slated to open across the Houston, Austin and San Antonio markets by the end of January. The three new San Antonio clinics will operate in affiliation with Methodist Healthcare System, San Antonio.
"Our Houston- and Austin-area RediClinics already have served more than [a] half-million satisfied patients," stated Web Golinkin, RediClinic’s CEO. "We look forward to responding to Texans’ growing need for access to primary and preventive health care by increasing our capacity in Houston and Austin, and by bringing our unique model of accessible and affordable care to San Antonio residents."
RediClinic, which currently operates 21 clinics, partners with healthcare systems in all of its markets. In addition to its new San Antonio affiliation with Methodist Healthcare System, RediClinic is affiliated with Memorial Hermann Healthcare System in Houston and St. David’s HealthCare in Austin.